ESMO 2020 Lung Cancer Conference Report

 

In Focus: Lung Cancer

Durvalumab Demonstrates Sustained Overall Survival in Unresectable Stage III NSCLC

Amivantamab-Lazertinib Combo for Resistant EGFR-positive NSCLC

Phase III ADAURA Trial: Life-Changing Results for NSCLC and CNS Metastases

Sotorasib Active in Patients with KRAS Mutation Shows Promise in NSCLC

PD-L1 Density a New Predictive Biomarker in NSCLC

No Advantage of Post-Op Radiotherapy in Patients with Stage IIIA N2 NSCLC

Bispecific Targeting PD-1 and CTLA-4: New Kids on the Block(ade)

Lorlatinib Outperforms Crizotinib in ALK-Positive Advanced NSCLC